Share on StockTwits

NanoViricides (NASDAQ:NNVC) released its earnings data on Tuesday. The company reported ($0.01) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.04) by $0.03, Analyst Ratings Network.com reports.

On the ratings front, analysts at Chardan Capital initiated coverage on shares of NanoViricides in a research note on Thursday, May 8th. They set a “buy” rating on the stock.

NanoViricides (NASDAQ:NNVC) opened at 3.22 on Tuesday. NanoViricides has a 52 week low of $2.03 and a 52 week high of $7.59. The stock’s 50-day moving average is $3.23 and its 200-day moving average is $4.25. The company’s market cap is $175.6 million.

NanoViricides, Incis a development-stage company. The Company is a nano-biopharmaceutical (NASDAQ:NNVC) company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.